Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Optimi Health ( (TSE:OPTI) ) has issued an announcement.
Optimi Health has successfully exported its natural psilocybin extract to New Zealand for a pioneering clinical trial aimed at addressing methamphetamine addiction through the integration of indigenous Māori knowledge and modern clinical methods. The initiative, supported by Tū Wairua and the Mātai Medical Research Institute, underscores a significant collaboration between indigenous leaders, health researchers, and industry partners to explore the therapeutic potential of psilocybin, while emphasizing cultural protocols and community well-being.
More about Optimi Health
Optimi Health Corp. is a Health Canada-licensed manufacturer specializing in psychedelic pharmaceuticals, specifically natural psilocybin and MDMA.
YTD Price Performance: 0.0%
Average Trading Volume: 70,172
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$19.88M
For an in-depth examination of OPTI stock, go to TipRanks’ Stock Analysis page.
